ARTICLE | Company News
GSK aims for 20 filings by 2020
November 4, 2015 2:15 AM UTC
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said at its R&D day Tuesday that it hopes to submit up to 20 pipeline candidates for approval by 2020, with an additional 20 filings to follow in 2021-25.
GSK highlighted six R&D areas of focus: HIV and infectious diseases, oncology, immuno-inflammation, vaccines, respiratory diseases and rare diseases. ...